Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06725524RecruitingPhase 1
New drug for B-cell lymphoma that returned after treatment
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
ShanghaiAges 18–70 - NCT07570017RecruitingPhase 1
Rocbrutinib Plus Chemotherapy for Resistant B-Cell Lymphoma
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Guangzhou, GuangdongAges 18 years+ - NCT07570173RecruitingPhase 2/Phase 3
MK-1045 for Hard-to-Treat B-Cell Leukemia
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
Toronto, OntarioAges 12 years+ - NCT07575308RecruitingPhase 2
ALN-6400 for Heavy Bleeding in von Willebrand Disease
This trial tests a new medicine called ALN-6400 in teenage and adult women with von Willebrand disease (a blood clotting condition) who experience heavy menstrual bleeding. The goal is to see if this treatment can reduce bleeding and improve quality of life.
Orange, CaliforniaAges 16–45 - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
Indianapolis, IndianaAges 18 years+ - NCT07570823RecruitingPhase 3
SCTB35 Plus Chemotherapy for Relapsed Lymphoma
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
BeijingAges 18–80 - NCT05053607Recruiting
Text and Fitbit monitoring during isatuximab treatment
This trial follows people with multiple myeloma who are getting isatuximab through a vein (IV). It tests how well real-world health tracking (text/app messages and Fitbit data) works during treatment, and whether it can help care teams understand your experience.
Houston, TexasAges 18 years+ - NCT05665140RecruitingPhase 2/Phase 3
Newly diagnosed myeloma study using blood-marker risk groups
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
BerlinAges 18–70 - NCT05170633Recruiting
Warming treatment for very preterm babies after blood transfusion
This study looks at whether a specific “blood warming” approach can help very preterm babies keep their body temperature from getting too low (hypothermia). It’s intended to reduce temperature drops around the time they receive red blood cell transfusions.
Columbia, South CarolinaAges 6 months–7 months - NCT07570407Recruiting
Blood Immune Cells After Bone Marrow Transplant for Leukemia
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Pilsen, CzechiaAges 18–70 - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07571096Recruiting
PCOS and Blood Clotting Risk Assessment Study
This study helps doctors better understand polycystic ovary syndrome (PCOS)—a hormonal condition affecting ovulation—and how it relates to blood clotting problems. Researchers will collect blood samples and health information to create a risk assessment tool.
Guangzhou, GuangdongAges 14–45 - NCT07576270Recruiting
Breathing exercises and massage after breast cancer surgery
This study tests whether special breathing exercises and massage techniques can help reduce pain, stiffness, and limited arm movement in people who've had breast cancer surgery. It may help improve shoulder function and quality of life after treatment.
Lahore, Punjab ProvinceAges 45–64 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT06665971RecruitingPhase 4
Dupilumab for esophagus muscle function in EoE
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
La Jolla, CaliforniaAges 22 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06150469Recruiting
Inhaled aromatherapy for nausea from chemo
This trial tests if smelling a blend of essential oils can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. You would use a simple inhaler stick whenever you feel sick.
BrivéAges 18 years+ - NCT06718270RecruitingEarly Phase 1
Study of CT0596 for Relapsed or Refractory Myeloma
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06730308RecruitingPhase 2
Steroids with chemoradiation for thymoma that can't be removed
This trial tests if adding a steroid (methylprednisolone) to standard chemotherapy and radiation helps people with thymoma that cannot be fully removed by surgery or has come back. The goal is to see if this combination works better at controlling the disease.
Guanzhou, GuangdongAges 18–75 - NCT06083207RecruitingPhase 1/Phase 2
IBI3003 for multiple myeloma that has returned or not responded
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
Wollongong, New South WalesAges 18 years+ - NCT07566494RecruitingPhase 1
Testing VAS-101 for sickle cell disease
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Bethesda, MarylandAges 18–90
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.